Genetic risk classification for adults with AML receiving less-intensive therapies: The 2024 ELN recommendations Journal Article

  

Authors:	Döhner, H.; DiNardo, C. D.; Appelbaum, F. R.; Craddock, C.; Dombret, H.; Ebert, B. L.; Fenaux, P.; Godley, L. A.; Hasserjian, R. P.; Larson, R. A.; Levine, R. L.; Miyazaki, Y.; Niederwieser, D.; Ossenkoppele, G.; Röllig, C.; Sierra, J.; Stein, E. M.; Tallman, M. S.; Tien, H. F.; Wang, J.; Wierzbowska, A.; Wei, A. H.; Löwenberg, B.
Article Title:	Genetic risk classification for adults with AML receiving less-intensive therapies: The 2024 ELN recommendations
Abstract:	The European LeukemiaNet (ELN) genetic risk classifications were developed based on data from younger adults receiving intensive chemotherapy. Emerging analyses from patients receiving less-intensive therapies prompted a proposal for an ELN genetic risk classification specifically for this patient population. © 2024 American Society of Hematology
Keywords:	adult; cancer chemotherapy; cancer combination chemotherapy; monotherapy; note; cancer patient; risk assessment; genetic risk; azacitidine; dna methyltransferase inhibitor; acute myeloid leukemia; human; venetoclax; ivosidenib
Journal Title:	Blood
Volume:	144
Issue:	21
ISSN:	0006-4971
Publisher:	American Society of Hematology
Date Published:	2024-11-21
Start Page:	2169
End Page:	2173
Language:	English
DOI:	10.1182/blood.2024025409
PROVIDER:	scopus
PUBMED:	39133932
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85203490901&doi=10.1182%2fblood.2024025409&partnerID=40&md5=4f19b0d2e302b2f472ce43c6249a92bb
Notes:	Note -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/220658